Board

Carsten Browall
Chairman of the board
Board Member Since 2018

 

Selected experience: Extensive experience of the medical device and healthcare sectors in senior positions in fast-growing companies such as Mölnlycke, Nobel Biocare, Capio, Vitrolife and Unfors RaySafe.

Shareholding in CELLINK:
Options: 160 000

Independent in relation to the Company and its management and in relation to major shareholders.

LinkedIn

Erik Gatenholm
Board Member Since 2016

Selected experience: Erik has a background in business management, an MBA from Gothenburg University and documented success in biotechnology entrepreneurship. His honors include Young Entrepreneur of the Year and Innovator of the Year, and he has been listed in Shortcut Magazine’s 100 Under 40 and prestigious Forbes 30 Under 30.

Shareholding in CELLINK:
A-stock: 828 124
B-stock: 10 028 036
Ownership: 32,6%
Voting right: 39,1%

Not Independent in relation to the Company and its management nor in relation to major shareholders.

LinkedIn

Artur Aira
Board Member Since 2017

Selected experience: Medical tech engineer and MBA by training. Prior to his role as Executive Vice President at AddLife, various leadership roles at Organon Teknika, bioMerieux and AddTech Life Science

Shareholding in CELLINK:
Options: 100 000

Independent in relation to the Company and its management and in relation to major shareholders.

LinkedIn

Helena Skåntorp
Board Member Since 2019

Selected experience: Helena Skåntorp was born 1960 and is a Swedish citizen. Helena Skåntorp has long experience from leading positions as CEO and CFO. She was CEO of Lernia 2011-2017, and prior to that, among other things CEO of Jarowskij AB and CFO of Arla. Helena started her career by working at PWC, mainly with auditing of listed companies and where she became an authorized accountant. Helena has been a member of boards of listed companies for more than 15 years.

Helena Skåntorp is currently devoting herself to her own business and work on various boards, among others, member of the board of directors of Mekonomen. She has degree of Master of Science in Business and Economics from Stockholm University and has also been a doctoral student at Stockholm School of Economics.

Shareholding in CELLINK:
B-stock: 4 000
Options: 40 000

Independent in relation to the company and its management as well as in relation to major shareholders.

LinkedIn

Ingela Hallberg
Board Member Since 2017

Selected experience: Doctor by training and after several years of working as physician, she has spent +20 years in leadership roles for various pharma industry leaders such as Bayer Healthcare, Lundbeck, Quintiles and Merck.

Shareholding in CELLINK:
Options: 90 000

Independent in relation to the Company and its management and in relation to major shareholders.

LinkedIn

Bengt Sjöholm
Board Member Since 2016

Selected experience: CEO of several Swedish companies, including Tylö, where he was CEO between 2004 and 2009. During the 1990s, Sjöholm was acting as CEO of a subsidiary of Getinge.

Shareholding in CELLINK:
B-stock: 188 276
Options: 100 000
Ownership: 0,56%
Voting right: 0,4%

Independent in relation to the Company and its management and in relation to major shareholders.

LinkedIn

Christian Wildmoser
Board Member Since 2019

Selected experience: Christian Wildmoser was born 1955 and is an Austrian citizen. Christian Wildmoser has worked within private equity for a long time and was a partner of CVC Capital Partners for 16 years, with responsibility for the operations in German-speaking Europe. Prior to that, he worked for 25 years in the banking sector, including investment banking.

Christian Wildmoser is today a private investor in developing companies. He is a Doctor of Economics from the University of Vienna.

Shareholding in CELLINK:
B-stock: 318 492‬
Options: 40 000
Ownership: 0.8 %
Voting rights: 0.6 %

Independent in relation to the company and its management as well as in relation to major shareholders.